CorMedix, Inc. (CRMD)

NASDAQ: CRMD · IEX Real-Time Price · USD
4.33
+0.61 (16.40%)
Aug 12, 2022 12:00 PM EDT - Market open
16.40%
Market Cap 169.40M
Revenue (ttm) 110,312
Net Income (ttm) -28.03M
Shares Out 39.12M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 550,736
Open 3.71
Previous Close 3.72
Day's Range 3.71 - 4.33
52-Week Range 2.65 - 8.03
Beta 2.21
Analysts Buy
Price Target 22.44 (+418.2%)
Earnings Date Aug 11, 2022

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as... [Read more...]

Industry Pharmaceuticals
IPO Date Mar 25, 2010
CEO Joseph Todisco
Employees 29
Stock Exchange NASDAQ
Ticker Symbol CRMD
Full Company Profile

Financial Performance

In 2021, CorMedix's revenue was $190,936, a decrease of -20.19% compared to the previous year's $239,231. Losses were -$28.21 million, 28.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for CRMD stock is "Buy." The 12-month stock price forecast is 22.44, which is an increase of 418.24% from the latest price.

Price Target
$22.44
(418.24% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern Time Conference Call Scheduled for Today at 8:30 a.m. Eastern Time

Why CorMedix Stock Was Plummeting on Tuesday

Bad news on the regulatory front leads investors to bail en masse from the company.

CorMedix Inc. Announces Regulatory and Manufacturing Updates

BERKELEY HEIGHTS, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

CorMedix to Participate at the JMP Securities Life Sciences Conference

BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

CorMedix Inc. Announces Leadership Updates and Operational Changes

BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and t...

CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12

BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

CorMedix Inc. Announces Scientific Advisory Board to Support Commercialization and Pipeline Development

BERKELEY HEIGHTS, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference

BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath

BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?

CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and...

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix, Inc. on Behalf of Long-Term Stockholders and E...

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CorMedix, Inc. (NASDAQ: CRMD) on behalf of...

CorMedix Inc. Announces the Appointment of Chief Executive Officer

Joseph Todisco to join CorMedix as Chief Executive Officer; Brings significant experience in commercial strategy, business operations and leadership, and specialty pharmaceuticals industry Joseph Todisc...

Cormedix Inc. Announces Resubmission of New Drug Application for DefenCath

BERKELEY HEIGHTS, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections

CorMedix Inc (NASDAQ: CRMD) has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the FDA.  In parallel, the Company's third-party manufact...

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of -22.22% and 280.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on November 9

BERKELEY HEIGHTS, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CorMedix Inc. Announces Abstracts at Upcoming Conferences Showing Patient Outcomes and Economic Burden of CRBSI

BERKELEY HEIGHTS, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

CorMedix Inc. Announces Executive Leadership Changes

BERKELEY HEIGHTS, N.J., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

LAWSUITS FILED AGAINST CRMD, ATVI and YALA - Jakubowitz Law Pursues Shareholders Claims

NEW YORK, NY / ACCESSWIRE / September 20, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies ...

Other symbols: ATVIYALA